COVID-19 leads to long-term changes in the immune system, study shows

In a study recently published in the renowned journal "Allergy", a MedUni Vienna research team shows that COVID-19 leads to considerable long-term changes in the immune system, even in mild cases. The findings could help to better understand the long-term consequences of an infection with SARS-CoV-2.

As part of the study, the team led by first authors Bernhard Kratzer and Pia Gattinger and principal investigators Rudolf Valenta and Winfried Pickl (all from MedUni Vienna's Center for Pathophysiology, Infectiology and Immunology) examined relevant immune parameters in 133 subjects who had recovered from COVID-19 and 98 subjects without the infection. The number and composition of various immune cells as well as cytokines and growth factors in the blood, which play a decisive role in the regulation of cell growth, were analysed in the recovered patients ten weeks and ten months after their initial infection . As no COVID-19 vaccines were available during the observational time period in 2020, all participants remained unvaccinated. This allowed the study authors to investigate the long-term effects of SARS-CoV-2 infection without the influence of vaccines.

Significant reduction of immune cells in the blood

Not entirely unexpectedly, ten weeks after the infection, the convalescent patients showed clear signs of immune activation of both their T and B cells, in contrast to healthy study subjects."

Winfried Pickl

In addition, the cytokines and growth factors in the blood were typical for remnants of an acute inflammatory process. A comparison with the patient samples obtained ten months after the COVID-19 disease revealed an unexpected picture to the researchers: "Even after mild disease progression, we found a significant reduction of immune cells in the blood," says Winfried Pickl, providing details from the study. In addition, the well-known drop in SARS-CoV-2-specific antibodies and an astonishing change in growth factor patterns in the blood were observed. For COVID-19 convalescent subjects, this means that their immune system may no longer be responding optimally to new challenges. This may provide an explanation for some of the observed sequelae of COVID-19, such as Long-COVID.

According to the researchers, the long-term consequences of COVID-19 are presumably caused by an infection and the resulting long-term impairment of the function of the bone marrow, the central production site of immune cells. "Our results provide a possible explanation that certain long-term consequences of COVID-19 could be related to the damage to the cellular immune system caused by SARS-CoV-2 and the apparently reduced maturation and/or emigration of immune cells from the bone marrow," Winfried Pickl and Rudolf Valenta summarize the study results. This hypothesis forms the basis for further research in order to achieve a better understanding of the mechanisms underlying Long-COVID.

Source:
Journal reference:

Kratzer, B., et al. (2024) Differential decline of SARS-CoV-2-specific antibody levels, innate and adaptive immune cells, and shift of Th1/inflammatory to Th2 serum cytokine levels long after first COVID-19. Allergy. doi.org/10.1111/all.16210.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
De novo antibody protein sequencing reveals novel functional and neutralizing antibodies post-SARS-CoV-2 vaccination